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Background: The evidence base to inform the decision making process in patients with early stage oral cancer and
a clinical and radiological N0 neck remains insufficient to answer the question when it is safe to “watch and wait”
and when to proceed with a selective neck dissection.
Methods: A total of 327 consecutive cases of histopathologically staged T1–2, N0–1 and M0, but clinically N0,
squamous cell carcinoma of the tongue were prospectively analysed. Univariate and multivariate analyses were
used for statistical analysis and are represented as Kaplan-Meier analyses or Cox proportional hazard regression
analysis.
Results: In 61 patients (18.65%) lymph node involvement was found in the histopathological processing. The mean
survival of all patients was 73.3 ± 48.6 months. The 2-year and 5-year overall survival rates of all patients were 87.5%
and 68.4%, respectively. The 2-year and 5-year survival rates for stage N0 were 89.1% and 70.7% compared to 83.3%
and 62.9% in N1 situations. The 2-year and 5-year survival rates for stage T1 were 87.9% and 73.6% compared to
87.2% and 65.3% in stage T2, respectively. The time to recurrence in stage N0 was 35.1 ± 30.5 months compared to
25.63 ± 24.6 months in cases with N1 disease. Stage T1 was associated with a time to recurrence of 38.1 ±
33.9 months compared with 27.2 ± 22.7 months in patients classified T2.
Variables found to be strongly associated with survival in the univariate analysis included older age, higher tumour
and N stage, and grading. Age, tumour stage (p = 0.011, 95% CI, 1.09 to 2.0), nodal stage (p = 0.038, 95% CI, 1.02 to
2.07), and recurrence were independently and significantly associated with survival in the multivariate analysis.
Conclusions: This confirms a high overall disease free survival for patients with T1 and N0 treated with single
modality surgery and in common with the literature confirms the poor impact on prognosis of the N positive neck.
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The incidence of pathologically positive lymph nodes in
the clinically and radiologically negative neck (N0) in T1
and T2 squamous cell carcinomas (SCC) of the oral cav-
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unless otherwise stated.is attempting to answer the question of when it is in the
best interests of the patient to carry out elective neck
dissection (SEND). Several single centre audits have
demonstrated an incidence of around 30% positive cer-
vical nodes in clinically and radiologically undetected
cases with T2 tongue and floor of mouth squamous can-
cer. Belief that only thin T2 and T1 SCC should not
undergo neck dissection (patient factors permitting) is
so strong that recruitment to the SEND study has been
slow. Surgery with or without radiation and chemother-
apy is the established curative treatment of SCC [1].
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modal treatment approaches including surgery and radio-
therapy with or without chemotherapy [2]. Although
ablative surgery with or without reconstruction is an
established therapy for small tumours staged at T1 and
T2 created controversies exists around the role of neck
dissection. Controversy also exists with radiation therapy
which is a single use treatment with lifelong post treat-
ment morbidity [3]. The management decision around
small stage T1 and T2 SCC particularly thin tumours cen-
ters around either a wait-and-see policy or a selective neck
dissection of the ipsilateral lymph nodes of level I-IV,
which logically should be bilateral in midline lesions [4,5].
The purpose of the present study was to investigate
the oncologic results and role of primary surgical treat-
ment for clinically early-stage SCC. The incidence of
lymph node involvement and its role in overall survival
was further investigated.Methods
Eligibility
Any patient who had histologically confirmed invasive
SCC of the tongue histopathologically staged T1–2, N0–1
and M0 was eligible. Exclusion criteria included previous
malignancy at the oral cavity or positive resection margins.Ethics and consent
Every patient gave an informed consent to participate in
clinical studies regarding the analyses of survival and
outcome of their treatments. Due to the informed con-
sent already given by patients to participate in studies
and willing to perform the required medical care an ex-
emption from requiring ethics approval was granted by
the Ethical Committee of the University of Munich.Staging
All patients underwent incisional biopsy, computed tom-
ography (CT) or magnetic resonance imaging (MRI),
skeletal scintigraphic surveys, sonography, and thoracic
x-ray. Lymph nodes of more than 1 cm with a rounded
configuration were regarded as probably involved by im-
aging criteria. In addition, clinical assessment was con-
trolled by CT and/or MRI scans as well as sonography
examination. All diagnostics were performed by an ex-
pert radiologist and individual cTNM was confirmed by
an interdisciplinary tumour board including specialists
from radiology, oral and maxillofacial surgery, ear nose
and throat surgeons, oncology, radiation therapy, and
nuclear medicine. Postoperative histopathological assess-
ment by the pathologists was used as the diagnostic gold
standard, retrospectively.Surgery
As part of the staging process all patients underwent
histological confirmation of the diagnosis. The extent of
neck dissection was performed uni- or bilaterally in level
I-III of the neck, depended on the location of metastases
intraoperatively [1]. The tumour resection was per-
formed surgically according to current guidelines and as
described before followed by microvascular reconstruc-
tion [6].
Follow-up
After surgery, patients were assessed every 3 months for
the first 2 years, every 6 months for another 2 years, and
every year thereafter. Investigations to detect recurrence
were done by clinical inspection and yearly CT routinely.
Data analysis
Data of the study were prospectively collected in one
single department and analysed. Overall survival in months
and 5-year overall survival were used as dependent vari-
ables. Associations of possible predictor variables with the
dependent variable, survival, were determined using the
Kaplan-Meier estimator, univariate log-rank test, and Cox
proportional hazards regression models. Multiple Cox pro-
portional hazards regression models were conducted to ex-
plore the relationship between neck involvement and
survival, as were variables shown in the literature to be as-
sociated with survival.
Measurements of tumour related differences were
compared using the non-parametric Fisher-test, as ap-
propriate. The Kaplan-Meier method was used to plot
survival curves for each putative binary prognostic fac-
tor. P-values are two-sided and subject to a global sig-
nificance level of 0.05. The data were analysed with the
“Statistical Package for the Social Sciences” (SPSS for
Windows, release 21, 2013, SPSS Inc, Chicago, IL, USA).
Results
General characteristics
From 1992 to 2008, of the 327 patients matching the cri-
teria were treated. Among these, 266 patients did not
show lymph node involvement histopathologically and in
61 patients (18.65%) lymph node involvement was found.
The median follow-up was 66 months (range 1–192). Pa-
tient demographic, clinical, and tumour characteristics are
summarized in Table 1.
Outcome
The mean survival of all patients was 73.3 ± 48.6 months.
The 2-year overall survival rate of all patients was
87.5%. 5-year overall survival rate of all patients was
68.4%. Among the patients with tumour stages classified
as T1 the overall survival rates were 87.9% and 73.6% at
2 and 5 years, respectively. The overall survivals in T2
Table 1 Demographic, Clinical, and Cancer Characteristics of all patients, with and without lymph node involvement
All patients Without lymph node involvement With lymph node involvement p-value
Characteristic No. % No. % No. %
Mean age (years) 60.6 60.25 62.28
SD 12.45 12.45 12.39
Range 30-91 30-91 30-91
Sex
Woman 105 32.1 82 78.1 23 21.9
0.215
Men 222 67.9 184 82.9 38 17.1
Performance status
Dead 129 39.4 98 76.0 31 24.0
0.074
Alive 198 60.6 168 84.8 30 15.2
Tumor stage
1 193 59.0 175 90.6 18 9.3
< 0.001*
2 134 41.0 91 67.9 43 32.1
N stage
0 266 81.3 266 100
1 61 18.7 61 100
Tumor grade
1 52 15.9 48 92.3 4 7.7
2 236 72.2 198 83.9 38 16.1 < 0.001*
3 39 11.9 20 51.3 19 48.7
Recurrence
0 257 78.6 214 83.3 43 16.7
0.083
1 70 21.4 52 74.3 18 25.7
Abbreviations: * p < 0.05.
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respectively. In patients without lymph node involvement
the 2-year overall survival rate was 89.1% compared to
83.3% of patient with stage N1. The corresponding 5-year
overall survival rates were 70.7% for patients without and
62.9% for patients with lymph node involvement at stage
N1. At the time of analysis, 198 (60.6%) patients were alive
and 129 (39.4%) had died. Subdividing patients who were
classified as tumour stage T1, the mean survival was
74.86 ± 49.3 months compared to 71.1 ± 47.48 in pa-
tients classified as T2; patients without lymph node in-
volvement had a mean survival of 74.17 ± 49.0 months
compared to 69.55 ± 46.7 months in patients staged as
N1. The time of recurrence was 38.1 ± 33.9 months in
patients classified at tumour stage T1 compared with
27.2 ± 22.7 months in patients classified T2. In patients
without lymph node involvement the time of recurrence
was 35.1 ± 30.5 months compared to 25.63 ± 24.6 months
in patients with N1 disease. A total of 70 patients (21.4%)
developed recurrences, 52 patients without lymph node
involvement and 18 with lymph node involvement
(Table 1). In relation to all patients without lymph node
involvement 19.5% developed recurrences (52/266),whereas 26.8% of patients (18/61) with lymph node in-
volvement developed recurrences.Univariate analysis
Variables found to be strongly associated with survival
in the univariate analysis included age, tumour and N
stage, and grading. The higher the age, tumour and N
stage, as well as the grading of the tumour, the more
negative was the effect on survival probability. There
was no relationship between survival and recurrence or
the sex of patient (Table 2). Kaplan-Meier analyses for
each variable significantly influencing survival are pre-
sented in Figures 1, 2, and 3.Multivariate analysis
Cox proportional hazard regression model analysis was
conducted controlling for age, tumour stage, nodal stage,
tumour grade, and recurrence. Sex was not associated
with survival in the univariate model and thus not in-
cluded in the multivariate analysis. Recurrence was also
included into the analysis as it has been reported to be a
significant factor associated with survival in the literature.
Table 2 Univariate Analysis for the factors influencing
overall survival (N = 327: 129 death events and 198
censored)
Variable Hazard ratio 95% CI p
Age 1.03 1.02 to 1.03 < 0.0001*
Tumor stage 1.252 1.16 to 1.35 = 0.01*
N stage 1.60 1.44 to 1.77 = 0.049*
Tumor grade 1.46 1.21 to 1.76 = 0.002*
Sex 1.02 0.83 to 1.25 0.365
Recurrence 1.23 1.00 to 1.52 0.911
Abbreviations: * p < 0.05.
Figure 2 Overall survival curves for the different T stages of
tongue carcinomas significantly influencing survival in
univariate analysis (p = 0.002).
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nodal stage (p = 0.038, 95% CI, 1.02 to 2.07), and recur-
rence were independently and significantly associated
with survival (Table 3). The higher the age, tumour, and
nodal stage, the more negative was the effect on survival
probability.
Discussion
In this study we reported the incidence of clinical occult
metastases in patients with T1 and T2 tongue squamous
cell carcinomas. Our outcomes have been presented
followed by conclusions based on our experience.
Our overall survival rates of our population of patients
are comparable with those from other studies and much
better than the frequently quoted crude overall survival
from oral cancer of 56% [7-9]. Therefore our results may
be extrapolated to patients from other countries withFigure 1 Overall survival curves for lymph node involvement
vs. no lymph node metastases significantly influencing survival
in univariate analysis (p = 0.049).similar staging. Management of the N0 neck in head and
neck squamous cell carcinoma is an important issue for
the head and neck surgeon. In patients with head and
neck cancer, the presence of lymph nodes metastases is
the most important prognostic factor [10]. The manage-
ment of patients with clinically negative nodes (N0) with
early tongue cancer is controversial. There are availableFigure 3 Overall survival curves for the different types of
tumour grading significantly influencing survival in univariate
analysis.
Table 3 Multivariate Analysis for the factors influencing
overall survival (N = 327: 129 death events and 198
censored)
Variable Hazard ratio 95% CI p
Age 1.04 1.02 to 1.05 < 0.0001*
Sex 1.11 0.73 to 1.71 = 0.622
Tumor stage 1.48 1.09 to 2.0 = 0.011*
N stage 1.68 1.04 to 2.74 = 0.034*
Recurrence 1.79 1.09 to 2.98 = 0.022*
Tumor grade 1.54 1.16 to 2.05 = 0.003*
Abbreviations: * p < 0.05.
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provided a satisfactory answer to the controversy [11-14].
There is a single randomised controlled trial attempting to
provide an evidence base for guidance on the definition of
a threshold of risk over which a neck dissection is indi-
cated. It is widely believed that tumour thickness will be
the most useful single determinant for this decision. Weiss
et al. 1994 concluded that N0 necks should be treated
electively when the occult metastatic rate is more than
20% [15].
In 61/327 patients lymph node involvement was dem-
onstrated. Studies have shown that a significant number
of patients with early oral cavity cancers who are observed
will develop neck recurrence and many of these recur-
rences will be of advanced stage with poor prognostic fac-
tors such as extra-capsular spread (ECS) [13]. The salvage
rates in these patients with recurrences were found to be
only 30% [12]. However we must bear in mind that there
are no available randomised controlled trials comparing
prophylactic treatment of the N0 neck with observation
and therapeutic neck dissection on detection of recur-
rence. There is a body of evidence from retrospective
studies suggesting that in patients who do not have
prophylactic therapy of the clinically N0 neck there is
often a low salvage rate on disease recurrence [16].
The diagnosis and treatment of oral cancer are nega-
tive predictors of health-related quality of life. In the oral
cavity both, a “wait and see” policy or an elective select-
ive neck dissection may be successful approaches tai-
lored to specific patients. The reality is that some
patients with oral cancer and N0 neck do not have oc-
cult metastases and would not benefit from an elective
neck dissection, some may have micrometastases but
there is no certainty that these will necessarily progress.
There are a group of patients with occult metastases
which do present later after primary treatment and have
a poorer outcome than would have been anticipated
from their original disease [9,12]. Current data has been
unable to provide recommendations based on sound evi-
dence. Especially in the clinical negative neck, shown in
this study, surprisingly, there is a high rate of occultmetastases within the lymph nodes of 18.65% of patients.
In the present study a large amount of patients were in-
cluded and even higher lymph node metastases rates
have been reported up to 42% in the past [12,13].
Conclusion
Even though staging of patients is still increasing by better
CT and MRI scanning there is a lack of evidence that pa-
tients with negative lymph node staging would benefit
from neck preservation. When we assess the literature we
must recognize that the poor salvage rates recorded were
based on work that was completed in the 80’s. Overall as
surgeons we may observe the neck more frequently and
this may be due to advances in the examination of nodal
status and potentially the higher detection rates of patients
with early lymph node metastases. Nevertheless, as stated
in the guidelines of oral cavity cancer neck dissections
should be performed as part of the concept to complete
the oncological therapy of this complex tumour entity in-
cluding its biological behaviour [17].
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TM: conception and design; acquisition of data; drafting and revising the
manuscript; DAM: conception and design; acquisition of data; drafting and
revising the manuscript. SW: analysis and interpretation of data; drafting and
revising the manuscript. LMR: analysis and interpretation of data; drafting
and revising the manuscript; KDW: analysis and interpretation of data;
drafting and revising the manuscript; AK: conception and design; acquisition
of data; drafting and revising the manuscript; All authors read and approved
the final manuscript and agree to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of any part of
the work are appropriately investigated and resolved.
Acknowledgements
This research was not funded. None of the authors received any funding for
this work.
Author details
1Department of Oral and Maxillofacial Surgery, Technische Universität
München, Klinikum Rechts der Isar, Ismaninger Str. 22, 81675 Munich,
Germany. 2Department of Oral and Maxillofacial Surgery, Oral and Facial
Specialties Department, Mid Yorkshire Hospitals NHS Trust, Aberford Road,
WF1 4DG West Yorks, UK. 3Institute for Medical Biometry, Epidemiology und
Medical Informatics (IMBEI), Universitätsklinikum des Saarlandes, Homburg/
Saar, Germany.
Received: 6 January 2014 Accepted: 14 May 2014
Published: 20 May 2014
References
1. Shah JP, Gil Z: Current concepts in management of oral cancer–surgery.
Oral Oncol 2009, 45(4–5):394–401.
2. Shingaki S, Takada M, Sasai K, Bibi R, Kobayashi T, Nomura T, Saito C: Impact
of lymph node metastasis on the pattern of failure and survival in oral
carcinomas. Am J Surg 2003, 185(3):278–284.
3. Mücke T, Koschinski J, Wagenpfeil S, Wolff KD, Kanatas A, Mitchell DA,
Deppe H, Kesting MR: Functional outcome after different oncological
interventions in head and neck cancer patients. J Cancer Res Clin Oncol
2012, 138(3):371–376.
4. Bar Ad V, Chalian A: Management of clinically negative neck for the
patients with head and neck squamous cell carcinomas in the modern
era. Oral Oncol 2008, 44(9):817–822.
Mücke et al. BMC Cancer 2014, 14:346 Page 6 of 6
http://www.biomedcentral.com/1471-2407/14/3465. Elsheikh MN, Rinaldo A, Ferlito A, Fagan JJ, Suarez C, Lowry J, Paleri V, Khafif
A, Olofsson J: Elective supraomohyoid neck dissection for oral cavity
squamous cell carcinoma: is dissection of sublevel IIB necessary?
Oral Oncol 2008, 44(3):216–219.
6. Mücke T, Wolff KD, Wagenpfeil S, Mitchell DA, Hölzle F: Immediate
microsurgical reconstruction after tumor ablation predicts survival
among patients with head and neck carcinoma. Ann Surg Oncol 2010,
17(1):287–295.
7. Brown JS, Magennis P, Rogers SN, Cawood JI, Howell R, Vaughan ED:
Trends in head and neck microvascular reconstructive surgery in
Liverpool (1992–2001). Br J Oral Maxillofac Surg 2006, 44(5):364–370.
8. Brown JS, Rogers SN, Lowe D: A comparison of tongue and soft palate
squamous cell carcinoma treated by primary surgery in terms of survival
and quality of life outcomes. Int J Oral Maxillofac Surg 2006, 35(3):208–214.
9. Zhang T, Lubek JE, Salama A, Dyalram D, Liu X, Ord RA: Treatment of
cT1N0M0 tongue cancer: outcome and prognostic parameters. J Oral
Maxillofac Surg 2013, 72(2):406–414.
10. Woolgar JA: Histopathological prognosticators in oral and oropharyngeal
squamous cell carcinoma. Oral Oncol 2006, 42(3):229–239.
11. Fakih AR, Rao RS, Patel AR: Prophylactic neck dissection in squamous cell
carcinoma of oral tongue: a prospective randomized study. Semin Surg
Oncol 1989, 5(5):327–330.
12. Ho CM, Lam KH, Wei WI, Lau SK, Lam LK: Occult lymph node metastasis in
small oral tongue cancers. Head Neck 1992, 14(5):359–363.
13. Kligerman J, Lima RA, Soares JR, Prado L, Dias FL, Freitas EQ, Olivatto LO:
Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell
carcinoma of oral cavity. Am J Surg 1994, 168(5):391–394.
14. Yuen AP, Ho CM, Chow TL, Tang LC, Cheung WY, Ng RW, Wei WI, Kong CK,
Book KS, Yuen WC, Trendell-Smith NJ, Chan YW, Wong BY, Li GK, Ho AC,
Womg SY, Yao TJ: Prospective randomized study of selective neck
dissection versus observation for N0 neck of early tongue carcinoma.
Head Neck 2009, 31(6):765–772.
15. Weiss MH, Harrison LB, Isaacs RS: Use of decision analysis in planning a
management strategy for the stage N0 neck. Arch Otolaryngol Head Neck
Surg 1994, 120(7):699–702.
16. Leon X, Quer M, Orus C, Sancho FJ, Bague S, Burgues J: Selective dissection
of levels II-III with intraoperative control of the upper and middle jugular
nodes: a therapeutic option for the N0 neck. Head Neck 2001,
23(6):441–446.
17. Wolff KD, Follmann M, Nast A: The diagnosis and treatment of oral cavity
cancer. Dtsch Arztebl Int 2012, 109(48):829–835.
doi:10.1186/1471-2407-14-346
Cite this article as: Mücke et al.: Incidence and outcome for patients
with occult lymph node involvement in T1 and T2 oral squamous cell
carcinoma: a prospective study. BMC Cancer 2014 14:346.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
